In patients with lung adenocarcinoma, tumors with p53 mutations had higher PD-L1 expression and higher levels of tumor-infiltrating cytotoxic T-cells as compared to tumors with wild-type p53 (Dong et al., 2017; Biton et al., 2018; Deniger et al., 2018). The gene discussed is TP53; the disease is lung adenocarcinoma.